ID

14606

Descrizione

Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00212043

collegamento

https://clinicaltrials.gov/show/NCT00212043

Keywords

versioni (1)
  1. 24/04/16 24/04/16 -
Caricato su

24 aprile 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Non Small Cell Lung Cancer NCT00212043

Inglese

Eligibility Non Small Cell Lung Cancer NCT00212043

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
• histologically or cytologically confirmed nsclc.
Descrizione

NSCL

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0007131
stage iiib unsuitable for radical radiation (eg. with cytologically proven malignant effusion) or stage iv disease as defined by the ajcc criteria (see appendix 1).
Descrizione

Staging

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0278984
UMLS CUI [2]
C0278987
karnofsky performance status 70% or higher (see appendix 2).
Descrizione

Karnofsky performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0206065
presence of at least one bidimensionally or unidimensionally measurable, non-cns, indicator lesion defined by radiologic study or physical examination.
Descrizione

Lesion defined by radiologic study or physical examination

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2071490
UMLS CUI [2]
C1290916
UMLS CUI [3]
C0031809
no previous chemotherapy for advanced disease. prior neoadjuvant or adjuvant chemotherapy, or chemotherapy given concurrently with radiotherapy for non-metastatic disease, is allowed if the last dose was given 6 months or more before study entry.
Descrizione

Chemotherapy or radiotherapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1522449
patients with recurrent disease after primary surgery and/or radiotherapy will be eligible.
Descrizione

Recurrent disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0277556
for patients with previous radiotherapy, the indicator lesion(s) must not be within previous radiation field. the last dose of radiotherapy should be at least 3 weeks prior to study entry. the total radiotherapy received should not be more than 30% of the bone marrow.
Descrizione

Radiotherapy: Specification

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1522449
UMLS CUI [2,1]
C0449685
UMLS CUI [2,2]
C1882536
UMLS CUI [3]
C2584899
UMLS CUI [4]
C0005953
screening laboratory criteria:
Descrizione

Laboratory procedures

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0022885
wbc count > 3500/microl neutrophils > 2000/microl platelet count > 100,000/microl hemoglobin > 9 g/dl (transfusion allowed)
Descrizione

WBC count, neutrophils, platelet count, hemoglobin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023508
UMLS CUI [2]
C0200633
UMLS CUI [3]
C0518015
serum creatinine < 133 micromol/l, or creatinine clearance > 30 ml/min, based on the cockcroft formula (see section 5.1.1)
Descrizione

Serum creatinine or creatinine clearance

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C2711451
bilirubin < 1.5 x upper limit of normal alt/ast < 2 x upper limit of normal if liver metastases are absent < 5 x upper limit of normal if liver metastases are present
Descrizione

bilirubin, alt/ast, liver metastases

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2]
C0201836
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0494165
aged 18 years and above.
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
life expectancy > 3 months.
Descrizione

Life expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
written informed consent.
Descrizione

Informed consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
• patients with only evaluable disease.
Descrizione

Evaluable disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1516986
active uncontrolled infection.
Descrizione

Infection

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0009450
pregnant or lactating women.
Descrizione

Gynaecological status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
females of childbearing potential who are unwilling to avoid pregnancy, for the duration of the study.
Descrizione

Contraception

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0700589
presence of any underlying medical conditions which in the investigators opinion would make the patient unsuitable for treatment.
Descrizione

Comorbidity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0009488
concomitant malignancies or previous malignancies other than nsclc within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma-in-situ of the cervix, or stage a low grade prostate cancer.
Descrizione

Further malignancies

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0332196
UMLS CUI [1,3]
C0007114
UMLS CUI [2,1]
C0006826
UMLS CUI [2,2]
C0332196
UMLS CUI [2,3]
C2216722
UMLS CUI [3,1]
C0006826
UMLS CUI [3,2]
C0332196
UMLS CUI [3,3]
C0376358
patients with cns and/or leptomeningeal metastases; unless asymptomatic and not receiving corticosteriod therapy.
Descrizione

CNS and leptomeningeal metastases, corticosteroid therapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2]
C1704231
UMLS CUI [3]
C0149783
Ritorna all'inizio della pagina

Similar models

Eligibility Non Small Cell Lung Cancer NCT00212043

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
NSCL
Item
• histologically or cytologically confirmed nsclc.
boolean
C0007131 (UMLS CUI [1])
Staging
Item
stage iiib unsuitable for radical radiation (eg. with cytologically proven malignant effusion) or stage iv disease as defined by the ajcc criteria (see appendix 1).
boolean
C0278984 (UMLS CUI [1])
C0278987 (UMLS CUI [2])
Karnofsky performance status
Item
karnofsky performance status 70% or higher (see appendix 2).
boolean
C0206065 (UMLS CUI [1])
Lesion defined by radiologic study or physical examination
Item
presence of at least one bidimensionally or unidimensionally measurable, non-cns, indicator lesion defined by radiologic study or physical examination.
boolean
C2071490 (UMLS CUI [1])
C1290916 (UMLS CUI [2])
C0031809 (UMLS CUI [3])
Chemotherapy or radiotherapy
Item
no previous chemotherapy for advanced disease. prior neoadjuvant or adjuvant chemotherapy, or chemotherapy given concurrently with radiotherapy for non-metastatic disease, is allowed if the last dose was given 6 months or more before study entry.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
Recurrent disease
Item
patients with recurrent disease after primary surgery and/or radiotherapy will be eligible.
boolean
C0277556 (UMLS CUI [1])
Radiotherapy: Specification
Item
for patients with previous radiotherapy, the indicator lesion(s) must not be within previous radiation field. the last dose of radiotherapy should be at least 3 weeks prior to study entry. the total radiotherapy received should not be more than 30% of the bone marrow.
boolean
C1522449 (UMLS CUI [1])
C0449685 (UMLS CUI [2,1])
C1882536 (UMLS CUI [2,2])
C2584899 (UMLS CUI [3])
C0005953 (UMLS CUI [4])
Laboratory procedures
Item
screening laboratory criteria:
boolean
C0022885 (UMLS CUI [1])
WBC count, neutrophils, platelet count, hemoglobin
Item
wbc count > 3500/microl neutrophils > 2000/microl platelet count > 100,000/microl hemoglobin > 9 g/dl (transfusion allowed)
boolean
C0023508 (UMLS CUI [1])
C0200633 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
Serum creatinine or creatinine clearance
Item
serum creatinine < 133 micromol/l, or creatinine clearance > 30 ml/min, based on the cockcroft formula (see section 5.1.1)
boolean
C0201976 (UMLS CUI [1])
C2711451 (UMLS CUI [2])
bilirubin, alt/ast, liver metastases
Item
bilirubin < 1.5 x upper limit of normal alt/ast < 2 x upper limit of normal if liver metastases are absent < 5 x upper limit of normal if liver metastases are present
boolean
C1278039 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0494165 (UMLS CUI [4])
Age
Item
aged 18 years and above.
boolean
C0001779 (UMLS CUI [1])
Life expectancy
Item
life expectancy > 3 months.
boolean
C0023671 (UMLS CUI [1])
Informed consent
Item
written informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Evaluable disease
Item
• patients with only evaluable disease.
boolean
C1516986 (UMLS CUI [1])
Infection
Item
active uncontrolled infection.
boolean
C0009450 (UMLS CUI [1])
Gynaecological status
Item
pregnant or lactating women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Contraception
Item
females of childbearing potential who are unwilling to avoid pregnancy, for the duration of the study.
boolean
C0700589 (UMLS CUI [1])
Comorbidity
Item
presence of any underlying medical conditions which in the investigators opinion would make the patient unsuitable for treatment.
boolean
C0009488 (UMLS CUI [1])
Further malignancies
Item
concomitant malignancies or previous malignancies other than nsclc within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma-in-situ of the cervix, or stage a low grade prostate cancer.
boolean
C0006826 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0007114 (UMLS CUI [1,3])
C0006826 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C2216722 (UMLS CUI [2,3])
C0006826 (UMLS CUI [3,1])
C0332196 (UMLS CUI [3,2])
C0376358 (UMLS CUI [3,3])
CNS and leptomeningeal metastases, corticosteroid therapy
Item
patients with cns and/or leptomeningeal metastases; unless asymptomatic and not receiving corticosteriod therapy.
boolean
C0686377 (UMLS CUI [1])
C1704231 (UMLS CUI [2])
C0149783 (UMLS CUI [3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial